A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

Pellegrino Musto, Maria Teresa Petrucci, Sara Bringhen, Tommasina Guglielmelli, Tommaso Caravita, Velia Bongarzoni, Alessandro Andriani, Giovanni D'Arena, Enrico Balleari, Giuseppe Pietrantuono, Mario Boccadoro, Antonio Palumbo

Research output: Contribution to journalArticlepeer-review


BACKGROUND. Bisphosphonates (BPs) are effective in the prevention and treatment of skeletal-related events (SREs) in patients with symptomatic myeloma who are receiving chemotherapy. Recent data also suggest a possible antineoplastic activity of BPs. Few studies published to date have explored the role of BPs in patients with untreated, asymptomatic myeloma (AM). No data are available on the efficacy of zoledronic acid in these patients. METHODS. The authors conducted a prospective, multicenter, open-label, phase 3, randomized trial comparing the administration of zoledronic acid versus simple observation in patients with AM. One-hundred sixty-three patients were enrolled and randomized (1:1) to receive zoledronic acid (n = 81 patients) or not to receive zoledronic acid (n = 82 patients) for 1 year at a dose of 4 mg monthly as a single, 15-minute, intravenous infusion. RESULTS. After a median follow-up of 64.7 person-months, 44.4% of patients in the zoledronic acid group and 45.1% of the control group progressed to 'symptomatic'myeloma requiring chemotherapy (P = .9307). The median time to progression was 67 months and 59 months for the treatment and control groups, respectively (P = .8312). At progression, SREs were significantly lower in the zoledronic acid-treated group (55.5%) than in the control group (78.3%; P = .041), whereas anemia, renal failure, and extramedullary disease were not statistically different. More frequent adverse events observed in the zoledronic acid-treated group were asymptomatic hypocalcemia and fever. One patient developed reversible osteonecrosis of the jaw. No renal failure caused by zoledronic acid was reported. CONCLUSIONS. The monthly use of zoledronic acid for 1 year in patients with AM reduced the development of SREs at progression but did not influence the natural history of the disease.

Original languageEnglish
Pages (from-to)1588-1595
Number of pages8
Issue number7
Publication statusPublished - Oct 1 2008


  • Asymptomatic myeloma
  • Bisphosphonates
  • Bone lesions
  • Multiple myeloma
  • Pamidronate
  • Zoledronate
  • Zoledronic acid

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma'. Together they form a unique fingerprint.

Cite this